Premium
Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance
Author(s) -
OjedaUribe Mario,
Caron Claudine,
ItzharBaikian Nathalie,
Debliquis Agathe
Publication year - 2010
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21692
Subject(s) - monoclonal gammopathy of undetermined significance , medicine , humanities , monoclonal , philosophy , monoclonal antibody , immunology , antibody
International audienceAcquired von Willebrand Syndrome (AVWS) is a rare heterogeneous bleeding condition associated with several disorders, including monoclonal gammopathy of undeterminated significance (MGUS) [1-3]. Successful therapy of the underlying disorder can leads to the improvement of AVWS [1]. Regarding the association of AVWS and MGUS, no long-term successful therapy has been reported. Indeed, most of these patients are not treated on a curative goal [1]. In a few single cases anti-CD20 targeted therapy (Rituximab) has shown no efficacy [4,5]. We describe herein the case of a patient with AVWS accompanied by MGUS who was successfully treated with the proteosome inhibitor Bortezomib after failure of Rituximab